Journal
ACTA CLINICA BELGICA
Volume 63, Issue 5, Pages 339-342Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1179/acb.2008.066
Keywords
hepatotoxicity; donepezil; jaundice; Alzheimer's disease; cholinesterase inhibitor
Categories
Ask authors/readers for more resources
Alzheimer's disease (AD) is the leading cause of dementia. It is characterized by the presence of senile plaques and neurofibrillary tangles in the brain, and impairment of the central cholinergic system, which contribute to memory toss and cognitive dysfunction. Cholinesterase inhibitors prevent the hydrolysis of acetylcholine and are currently approved for the symptomatic treatment of Alzheimer's disease. Donepezil, a piperidine-based, reversible and specific inhibitor of acetylcholinesterase, has been demonstrated to be clinically effective in the treatment of patients with mild to moderate AD. To date, clinical trials have not reported an association between treatment with donepezil and hepatotoxicity. We describe a case of toxic hepatitis, documented by liver biopsy, in a patient treated with donepezil.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available